Shayna Rae Sarosiek, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Waldenstrom Macroglobulinemia | 24 | 2024 | 1052 | 5.370 |
Why?
|
| Melphalan | 12 | 2023 | 431 | 3.010 |
Why?
|
| Amyloidosis | 8 | 2023 | 796 | 2.010 |
Why?
|
| Adenine | 8 | 2024 | 936 | 1.710 |
Why?
|
| Vena Cava Filters | 4 | 2017 | 253 | 1.430 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2020 | 627 | 1.190 |
Why?
|
| Piperidines | 9 | 2024 | 1602 | 1.110 |
Why?
|
| Lymphoma, B-Cell | 5 | 2023 | 931 | 1.060 |
Why?
|
| Myeloid Differentiation Factor 88 | 7 | 2023 | 571 | 1.040 |
Why?
|
| Receptors, CXCR4 | 5 | 2021 | 727 | 1.010 |
Why?
|
| Protein Kinase Inhibitors | 12 | 2023 | 5534 | 0.770 |
Why?
|
| Thrombocytopenia | 2 | 2019 | 1178 | 0.760 |
Why?
|
| Amyloid Neuropathies, Familial | 3 | 2023 | 138 | 0.730 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2019 | 272 | 0.730 |
Why?
|
| Antineoplastic Agents | 10 | 2023 | 13693 | 0.720 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 8 | 2023 | 5445 | 0.720 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 2 | 2022 | 177 | 0.710 |
Why?
|
| Prealbumin | 2 | 2018 | 210 | 0.700 |
Why?
|
| Ketotifen | 1 | 2019 | 21 | 0.680 |
Why?
|
| Chalazion | 1 | 2019 | 13 | 0.670 |
Why?
|
| Defibrillators | 1 | 2019 | 37 | 0.670 |
Why?
|
| Hypocalcemia | 1 | 2020 | 191 | 0.660 |
Why?
|
| Histamine H1 Antagonists | 1 | 2019 | 100 | 0.650 |
Why?
|
| Membranes, Artificial | 1 | 2019 | 378 | 0.610 |
Why?
|
| Sulfonamides | 3 | 2024 | 1940 | 0.610 |
Why?
|
| Conjunctivitis | 1 | 2019 | 158 | 0.610 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2019 | 426 | 0.590 |
Why?
|
| Vena Cava, Inferior | 2 | 2017 | 440 | 0.580 |
Why?
|
| Stem Cell Transplantation | 3 | 2020 | 1620 | 0.560 |
Why?
|
| Hepatomegaly | 1 | 2015 | 85 | 0.530 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2021 | 570 | 0.510 |
Why?
|
| Fractures, Compression | 1 | 2015 | 133 | 0.460 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2013 | 87 | 0.440 |
Why?
|
| Multiple Myeloma | 6 | 2022 | 5181 | 0.440 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2021 | 11525 | 0.440 |
Why?
|
| Renal Dialysis | 2 | 2019 | 1783 | 0.440 |
Why?
|
| Bone Density Conservation Agents | 1 | 2020 | 772 | 0.430 |
Why?
|
| Mediastinal Diseases | 1 | 2013 | 89 | 0.430 |
Why?
|
| Molecular Targeted Therapy | 2 | 2023 | 2725 | 0.420 |
Why?
|
| Kidney Diseases | 1 | 2023 | 2148 | 0.420 |
Why?
|
| Prosthesis Implantation | 1 | 2017 | 642 | 0.410 |
Why?
|
| Flow Cytometry | 2 | 2021 | 5974 | 0.390 |
Why?
|
| Heparin | 1 | 2018 | 1637 | 0.380 |
Why?
|
| Immunoglobulin Light Chains | 4 | 2022 | 277 | 0.380 |
Why?
|
| Transplantation, Autologous | 5 | 2023 | 2124 | 0.360 |
Why?
|
| Immunotherapy | 2 | 2023 | 4446 | 0.350 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 3595 | 0.350 |
Why?
|
| Amyloid | 2 | 2022 | 795 | 0.350 |
Why?
|
| Spinal Fractures | 1 | 2015 | 696 | 0.320 |
Why?
|
| Mutation, Missense | 1 | 2018 | 2566 | 0.320 |
Why?
|
| Dexamethasone | 5 | 2023 | 1951 | 0.300 |
Why?
|
| Humans | 63 | 2024 | 744366 | 0.290 |
Why?
|
| Aged | 30 | 2024 | 163288 | 0.280 |
Why?
|
| Pyrazoles | 5 | 2023 | 1972 | 0.270 |
Why?
|
| Thrombosis | 2 | 2018 | 2968 | 0.250 |
Why?
|
| Cyclophosphamide | 4 | 2023 | 2242 | 0.250 |
Why?
|
| Pyrimidines | 5 | 2023 | 2943 | 0.240 |
Why?
|
| Wounds and Injuries | 1 | 2017 | 2400 | 0.240 |
Why?
|
| Pulmonary Embolism | 4 | 2019 | 2375 | 0.240 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2024 | 2269 | 0.230 |
Why?
|
| Middle Aged | 27 | 2021 | 213390 | 0.230 |
Why?
|
| Male | 31 | 2023 | 350115 | 0.230 |
Why?
|
| Hospital Mortality | 1 | 2017 | 5316 | 0.220 |
Why?
|
| Transplantation Conditioning | 2 | 2019 | 1599 | 0.200 |
Why?
|
| Survival Rate | 6 | 2021 | 12788 | 0.190 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2023 | 233 | 0.190 |
Why?
|
| Retrospective Studies | 12 | 2023 | 77460 | 0.180 |
Why?
|
| HTLV-II Infections | 1 | 2019 | 4 | 0.180 |
Why?
|
| Female | 28 | 2023 | 380193 | 0.180 |
Why?
|
| Aged, 80 and over | 11 | 2021 | 57776 | 0.180 |
Why?
|
| Venous Thromboembolism | 3 | 2019 | 1671 | 0.180 |
Why?
|
| Hyperpigmentation | 1 | 2021 | 112 | 0.180 |
Why?
|
| Adult | 21 | 2023 | 214052 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2020 | 299 | 0.170 |
Why?
|
| Paraproteinemias | 1 | 2022 | 246 | 0.170 |
Why?
|
| HTLV-I Infections | 1 | 2019 | 101 | 0.170 |
Why?
|
| Neoplasm, Residual | 2 | 2021 | 973 | 0.170 |
Why?
|
| Device Removal | 2 | 2016 | 656 | 0.170 |
Why?
|
| Edema | 1 | 2023 | 789 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2020 | 417 | 0.170 |
Why?
|
| Point Mutation | 2 | 2021 | 1624 | 0.160 |
Why?
|
| Sterilization | 1 | 2019 | 133 | 0.160 |
Why?
|
| Leukapheresis | 1 | 2018 | 131 | 0.160 |
Why?
|
| Brachial Plexus Neuritis | 1 | 2017 | 20 | 0.160 |
Why?
|
| Prevalence | 3 | 2020 | 15221 | 0.160 |
Why?
|
| Organ Specificity | 2 | 2021 | 2008 | 0.160 |
Why?
|
| Ophthalmic Solutions | 1 | 2019 | 317 | 0.150 |
Why?
|
| Drug Resistance | 1 | 2023 | 1608 | 0.150 |
Why?
|
| Sulfones | 1 | 2019 | 436 | 0.140 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2020 | 260 | 0.140 |
Why?
|
| Platelet Count | 1 | 2019 | 780 | 0.140 |
Why?
|
| Thrombophilia | 1 | 2019 | 305 | 0.140 |
Why?
|
| Heart | 2 | 2020 | 4464 | 0.140 |
Why?
|
| Herpesvirus 4, Human | 1 | 2021 | 1041 | 0.140 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2016 | 188 | 0.140 |
Why?
|
| Thalidomide | 1 | 2021 | 890 | 0.130 |
Why?
|
| Benzamides | 1 | 2021 | 1379 | 0.130 |
Why?
|
| Bone Marrow | 4 | 2021 | 2948 | 0.130 |
Why?
|
| Pyrazines | 1 | 2021 | 1230 | 0.130 |
Why?
|
| Treatment Outcome | 9 | 2023 | 63107 | 0.130 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2015 | 134 | 0.130 |
Why?
|
| Translocation, Genetic | 1 | 2020 | 1420 | 0.120 |
Why?
|
| Liver | 3 | 2020 | 7475 | 0.120 |
Why?
|
| Kidney | 2 | 2020 | 7184 | 0.120 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2023 | 2455 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 6539 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 9274 | 0.110 |
Why?
|
| Mutation | 6 | 2023 | 29786 | 0.110 |
Why?
|
| Remission Induction | 1 | 2019 | 2385 | 0.110 |
Why?
|
| Disease-Free Survival | 2 | 2021 | 6896 | 0.110 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 1793 | 0.110 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 1782 | 0.110 |
Why?
|
| Minority Groups | 1 | 2020 | 1221 | 0.110 |
Why?
|
| Polymers | 1 | 2019 | 1621 | 0.100 |
Why?
|
| Alkaline Phosphatase | 1 | 2015 | 867 | 0.100 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 1596 | 0.100 |
Why?
|
| Immunologic Factors | 1 | 2021 | 1580 | 0.100 |
Why?
|
| Plasma Cells | 1 | 2015 | 591 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 10943 | 0.100 |
Why?
|
| Hospitals, University | 1 | 2013 | 570 | 0.100 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2013 | 504 | 0.100 |
Why?
|
| Follow-Up Studies | 6 | 2021 | 39052 | 0.100 |
Why?
|
| Neoplasms | 1 | 2020 | 21696 | 0.100 |
Why?
|
| Biocompatible Materials | 1 | 2019 | 1736 | 0.090 |
Why?
|
| Review Literature as Topic | 1 | 2013 | 336 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2020 | 10252 | 0.090 |
Why?
|
| Consensus | 3 | 2023 | 2960 | 0.090 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2019 | 1378 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 2 | 2018 | 2535 | 0.080 |
Why?
|
| Prospective Studies | 6 | 2022 | 53290 | 0.080 |
Why?
|
| Medical Records | 1 | 2013 | 1413 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2020 | 9849 | 0.070 |
Why?
|
| Prognosis | 4 | 2021 | 29060 | 0.070 |
Why?
|
| Dietary Supplements | 1 | 2020 | 3296 | 0.070 |
Why?
|
| Calcium | 1 | 2020 | 5755 | 0.070 |
Why?
|
| Kidney Transplantation | 2 | 2018 | 4251 | 0.070 |
Why?
|
| Patient Selection | 1 | 2018 | 4216 | 0.070 |
Why?
|
| Myocardium | 1 | 2019 | 4772 | 0.070 |
Why?
|
| Cause of Death | 1 | 2017 | 3582 | 0.070 |
Why?
|
| Fatal Outcome | 2 | 2021 | 1851 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2022 | 1434 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 3154 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 12356 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2016 | 2531 | 0.060 |
Why?
|
| Recurrence | 3 | 2020 | 8340 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-hck | 1 | 2022 | 46 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3135 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3242 | 0.050 |
Why?
|
| Time Factors | 3 | 2021 | 40075 | 0.050 |
Why?
|
| Young Adult | 2 | 2019 | 56429 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 15535 | 0.050 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2021 | 173 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 12961 | 0.040 |
Why?
|
| src-Family Kinases | 1 | 2022 | 551 | 0.040 |
Why?
|
| Lymph Nodes | 2 | 2021 | 3476 | 0.040 |
Why?
|
| Vincristine | 1 | 2021 | 1039 | 0.040 |
Why?
|
| Disease Progression | 3 | 2021 | 13286 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2017 | 21748 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2020 | 23336 | 0.040 |
Why?
|
| Upper Extremity | 1 | 2023 | 648 | 0.040 |
Why?
|
| Melanoma | 1 | 2016 | 5511 | 0.040 |
Why?
|
| Myeloablative Agonists | 1 | 2019 | 218 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2013 | 4600 | 0.040 |
Why?
|
| Paraproteins | 1 | 2017 | 39 | 0.040 |
Why?
|
| Virus Activation | 1 | 2019 | 319 | 0.040 |
Why?
|
| Child | 2 | 2017 | 77709 | 0.040 |
Why?
|
| Adolescent | 2 | 2017 | 85779 | 0.040 |
Why?
|
| Autopsy | 1 | 2020 | 1020 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 8642 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 551 | 0.040 |
Why?
|
| Prednisone | 1 | 2021 | 1574 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 1537 | 0.030 |
Why?
|
| HIV Infections | 1 | 2021 | 16715 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2021 | 2234 | 0.030 |
Why?
|
| Spleen | 1 | 2020 | 2362 | 0.030 |
Why?
|
| Physical Therapy Modalities | 1 | 2017 | 550 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 9240 | 0.030 |
Why?
|
| Risk Factors | 1 | 2020 | 72296 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 4185 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2022 | 2917 | 0.020 |
Why?
|
| Infant | 1 | 2013 | 35134 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2017 | 1275 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2013 | 41005 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2016 | 1461 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 20130 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2023 | 4666 | 0.020 |
Why?
|
| Proteomics | 1 | 2022 | 3638 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 3707 | 0.020 |
Why?
|
| Graft Survival | 1 | 2018 | 3737 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 35425 | 0.020 |
Why?
|
| Incidence | 1 | 2021 | 20952 | 0.010 |
Why?
|
| United States | 2 | 2021 | 69872 | 0.010 |
Why?
|
| Lung | 1 | 2020 | 9857 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 7282 | 0.010 |
Why?
|
| Quality of Life | 1 | 2022 | 12802 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8385 | 0.010 |
Why?
|
| Mice | 1 | 2022 | 81201 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2017 | 40559 | 0.010 |
Why?
|
| Animals | 1 | 2022 | 168768 | 0.010 |
Why?
|